Press Release
Jun
15
Press Release．2026
TWi Biotechnology Announces Completion of Primary Endpoint Assessment in Global Phase 2/3 Pivotal Trial of AC-203; Q4 Unblinding Countdown Begins as Company Aims to Deliver the World’s First Treatment for EBS
Jun
01
Press Release．2026
TWi Biotechnology Initiates Phase 2a Clinical Trial of AC-1101 for Alopecia areata as AC-203 Approaches Key Readout Milestone
Apr
22
Press Release．2026
TWi Biotechnology Announces Collaboration with EB House Austria to Explore AC-203 for the Treatment of Dystrophic Epidermolysis Bullosa
Apr
14
Press Release．2026
TWi Biotechnology Announces Completion of Patient Enrollment for the Global Phase 2/3 Trial of AC-203 in Treating Epidermolysis Bullosa Simplex (EBS)
Feb
05
Press Release．2026
Announces Interim Analysis Results from the Global Phase 2/3 Clinical Trial of AC-203 for the Treatment of Epidermolysis Bullosa Simplex (EBS)
Nov
20
Press Release．2025
Our Deepest Appreciation to All Shareholders Who Stand Behind Us.
Nov
16
Press Release．2025
Key Efficacy Results of NORA520 Phase II Clinical Trial for the Treatment of Postpartum Depression (PPD)
Nov
16
Press Release．2025
TWi Biotechnology (Stock Code: 6610) Announces Key Efficacy Results from the Phase II Clinical Trial of NORA520 for the Treatment of Postpartum Depression (PPD)
Oct
16
Press Release．2025
Announcement: The Company Has Received the Type C Meeting Minutes from the U.S. FDA
Sep
30
Press Release．2025
TWi Biotechnology Announces September 30, 2025 as the Effective Date of Merger with DK Pharma
Sep
24
Press Release．2025
TWi Biotechnology Receives 2025 Taipei Biotech Awards
Jun
06
Press Release．2025
TWi Biotechnology and DuKang Pharmaceuticals Announce Merger Approval by Shareholders– Target Effective Date Set for September 30, 2025
Apr
21
Press Release．2025
TWi Biotechnology Announces Merger with Dukang Pharmaceuticals: Unlocking Synergies, Integrating Resources, Expanding Pipeline, and Enhancing Shareholder Value
Apr
08
Press Release．2025
AC-203 has received approval from the India to conduct Phase 2/3 clinical trial
Jan
06
Press Release．2025
TWi Biotechnology Signs Exclusive License Term Sheet with R-Pharm for AC-203 to Treat Epidermolysis Bullosa Simplex
/
4
